#oral health in COVID-19

[wellhealthhub]

Efficient Solutions for Tonsillitis White Patches: A Comprehensive Guide

Discover the underlying reasons behind white spots on tonsils, grasp their symptoms, and explore a spectrum of treatment options in this comprehensive guide that balances medical insights with patient-centered perspectives. Tonsils, those guardians of our throats, occasionally present an unsettling spectacle with the appearance of white spots. The interplay between the discomfort caused by these…

[covid-safer-hotties]

The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits - Published Sept 6, 2024

By: Rita Rubin, MA

As another COVID-19 summer surge hit the US this year, many infected people likely were prescribed the antivirals nirmatrelvir and ritonavir, better known as Paxlovid, for the first time. Or for the fourth time. Or somewhere in between.

Nirmatrelvir-ritonavir, the only approved oral therapy for COVID-19, is recommended for treating mild to moderate SARS-CoV-2 infections among people who are at high risk of progression to severe disease. This includes people aged 50 years or older, especially those 65 years or older, as well as younger individuals who have any of a long list of comorbidities that increase the risk of severe COVID-19.

The clinical trials leading to the US Food and Drug Administration (FDA) authorizing emergency use of nirmatrelvir-ritonavir in December 2021 and approving it in May 2023 were conducted with unvaccinated people who were infected with the now long-gone SARS-CoV-2 Delta variant. This has led to questions about its effectiveness for people who have been vaccinated or have been infected with subvariants of Delta’s successor Omicron, which have been circulating for nearly 3 years.

But recent observational studies suggest nirmatrelvir-ritonavir still protects people at high risk against hospitalization and death from COVID-19. That is if they’re able to get a prescription for it—research has uncovered racial and ethnic disparities in which eligible patients get a prescription for the treatment.

And as the number of people with postacute sequelae of SARS-CoV-2 infection (PASC), or long COVID, grows, scientists have been investigating whether nirmatrelvir-ritonavir might be useful in protecting against or treating the condition.

Does It Still Prevent Severe COVID-19?

Because the nirmatrelvir-ritonavir phase 2 and 3 trial involved unvaccinated adults without prior COVID-19 infection when the Delta variant dominated, questions have remained about its relevance today.

Scientists from Pfizer, which markets nirmatrelvir-ritonavir, and coauthors recently published a systematic literature review examining that question. They searched for real-world studies reported from December 2021 through March 2023 and identified 18 that met their final selection criteria.

The evidence showed that nirmatrelvir-ritonavir was effective regardless of age, underlying high-risk conditions, or vaccination status. The treatment significantly reduced the postinfection risk of all-cause and COVID-19–related mortality both within the first 30 days and in the long-term. Treatment started within 5 days of symptom onset, as recommended on the label, was associated with the greatest reduction in postinfection risk.

“We remain very confident in Paxlovid’s clinical effectiveness at preventing severe outcomes, including hospitalization and death, from COVID-19 in patients at high risk of severe disease,” Pfizer spokesperson Kit Longley said in an early August email.

Another recently published study reached a somewhat different conclusion. That study, conducted by University of Manitoba researchers, analyzed results from 4 randomized trials and 16 real-world studies, some of which had not yet been peer-reviewed, with a total of nearly 2 million adults aged 18 years or older.

The evidence suggested nirmatrelvir-ritonavir has a small but significant efficacy in reducing COVID-19 hospitalization and all-cause mortality among people with laboratory-confirmed mild to moderate infections, but the evidence is weak, so more studies are needed, the authors concluded.

At Risk but No Script

COVID-19 laid bare health disparities in the US, and nirmatrelvir-ritonavir has been no exception, according to a study published in August.

Using National COVID Cohort Collaborative (N3C) data, researchers studied individuals 18 years of age or older who were diagnosed with COVID-19 between January 2022 and December 2023; up until the end of that period, the US government covered the cost of nirmatrelvir-ritonavir for everyone who needed it.

About 1.26 million people in the N3C cohort were at high risk of progressing to severe disease, making them eligible for nirmatrelvir-ritonavir treatment. But overall, nearly two-thirds of those who were eligible weren’t prescribed the treatment, the authors observed. After accounting for age, sex, and clinical characteristics, the researchers found that non-Hispanic Black and Latino individuals were nearly a third less likely to have used nirmatrelvir-ritonavir than non-Hispanic White individuals.

Patients may not seek care or may not seek it out early enough for the treatment to be effective, coauthor Hemalkumar Mehta, PhD, a core member of the N3C, speculated in an interview with JAMA Medical News.

Another reason could be that patients don’t have a regular source of primary care whom they could ask for a prescription, noted Mehta, a pharmacist and epidemiologist at the Johns Hopkins Bloomberg School of Public Health. They likely don’t know that the FDA has authorized state-licensed pharmacists to prescribe nirmatrelvir-ritonavir, he said.

Mehta acknowledged that until he conducted his study, even he didn’t realize that pharmacists could prescribe the COVID-19 treatment. Publicizing that fact by simply hanging a sign in pharmacies would help, he pointed out.

However, the FDA created an obstacle to quick prescribing of nirmatrelvir-ritonavir by pharmacists, a 2023 article noted. Prior to prescribing, pharmacists must assess patients’ liver and kidney function through health records from the previous 12 months or consultation with their clinician. Other prescribers can simply ask patients about their liver and kidney function and take their word for it, the authors explained. In addition, there is no standardized pathway for pharmacists to bill payors for assessing patients to see if they’re eligible for nirmatrelvir-ritonavir, which typically takes 15 to 30 minutes, according to the American Pharmacists Association.

When people do get a prescription for nirmatrelvir-ritonavir, most get it filled, a recently published study of Walgreens pharmacies nationwide data found. The retrospective study included people 12 years of age or older for whom a nirmatrelvir-ritonavir prescription was ordered from Walgreens pharmacies between December 2021 and August 2023.

A total of about 2.1 million nirmatrelvir-ritonavir prescriptions were ordered for about 2 million individuals. Among the 95% of people who were prescribed only 1 course of the treatment, 88% filled their prescription. Improving uptake of nirmatrelvir-ritonavir requires increasing patient and prescriber awareness, reducing prescribing disparities, and ensuring treatment initiation within 5 days of symptom onset, the authors concluded.

Treat Acute Infection, Prevent Long COVID?

Taking nirmatrelvir-ritonavir for acute COVID-19 might protect against long COVID, although research into that topic has had mixed results.

For example, 2 recent studies, neither of which had yet been peer-reviewed, reached different conclusions.

A preprint posted in June reported observational study results from the Researching COVID to Enhance Recovery (RECOVER) initiative funded by the US National Institutes of Health (NIH). The study population included nearly 500 000 people who tested positive for SARS-CoV-2 between March 2022 and February 2023. Of those, about 165 000 were treated with nirmatrelvir-ritonavir within 5 days after becoming infected.

Compared with no treatment, nirmatrelvir-ritonavir therapy was associated with a 12% lower risk of developing long COVID within 180 days of infection, or an absolute risk reduction of about 3 cases per 100 people. However, no such risk reduction was seen in people at low risk of severe COVID-19 infection who received nirmatrelvir-ritonavir.

“There are quite a few patients who are not at risk but who received a Paxlovid prescription,” first author Fei Wang, PhD, explained in an interview with JAMA Medical News. “This provides us an opportunity to evaluate a low-risk population that got COVID.”

Another preprint, posted this summer, used N3C electronic health records. It found that nirmatrelvir-ritonavir treatment of acute COVID-19 was not significantly associated with reducing long COVID overall, although it was linked to fewer cognitive and fatigue symptoms.

The mixed findings between the 2 studies aren’t surprising, said Wang, an assistant professor of health care policy and research at Weill Cornell Medicine.

Some information, such as COVID-19 vaccination history and nirmatrelvir-ritonavir use, isn’t always encoded in electronic health records, Wang pointed out. Although he and his colleagues “spend a lot of effort” to make sure they have complete patient information, Wang explained, “there’s no way we can evaluate how complete that is.”

He added that not having a consensus definition of long COVID is another critical issue. The N3C’s definition isn’t the same as RECOVER’s, and the 2 cohorts have different patient populations. “All these can lead to different results,” he said.

For Wang, it makes sense that taking nirmatrelvir-ritonavir, an antiviral, for acute COVID-19 would protect against long COVID. The severity of acute SARS-CoV-2 infections is correlated with the risk of long COVID, he said, and one theory about the cause of PASC is the persistence of SARS-CoV-2 in the body.

However, Yale cardiologist Harlan Krumholz, MD, SM, pointed out that unidentified confounders, not nirmatrelvir-ritonavir itself, might be at play in the relationship between treating acute SARS-CoV-2 infection and long COVID risk. “People who take Paxlovid might be different in many other ways,” he noted.

A Long COVID Treatment?

Many individuals with long COVID didn’t have the opportunity to take nirmatrelvir-ritonavir when they first became ill with acute COVID-19. They might have been infected before the treatment became available, or they weren’t considered to be at high risk for severe disease, so they weren’t eligible for it.

Some case reports have suggested that it might not be too late for people who’ve had long COVID for months to benefit from nirmatrelvir-ritonavir. For example, in early 2023 internist Linda Geng, MD, PhD, codirector of Stanford’s PASC clinic, and coauthors reported the case of a patient who’d had long COVID for 7 months, around which time the symptoms of acute COVID-19 returned. Although rapid antigen test results were negative, the patient had been exposed to multiple people with COVID-19, so a primary care physician prescribed nirmatrelvir-ritonavir. Not only did the acute flu-like symptoms resolve, but so did the long COVID symptoms, which included severe fatigue and cognitive difficulties.

That patient spurred Geng and her colleagues to conduct what they say is the first published randomized trial of nirmatrelvir-ritonavir to treat PASC, which appeared in June in JAMA Internal Medicine. The trial enrolled 155 participants with long COVID, all but 2 of whom had received the primary COVID-19 vaccination series. On average, the time between their initial SARS-CoV-2 infection and randomization into the trial was about a year and a half.

The trial found that the longer 15-day course of nirmatrelvir-ritonavir it used was generally safe. However, the treatment didn’t significantly improve long COVID symptoms compared with the control group.

It’s far from the final answer about nirmatrelvir-ritonavir’s effectiveness against long COVID, though, Geng noted. “This is just the first step in many investigations that need to be done.”

The NIH is funding several clinical trials targeting long COVID under the RECOVER initiative umbrella. One, the Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms (RECOVER-VITAL), is testing an even longer course of nirmatrelvir-ritonavir among an estimated 900 participants at centers throughout the US.

And Krumholz and colleagues at Yale University are in the process of analyzing data from their placebo-controlled randomized trial of nirmatrelvir-ritonavir in 100 patients with long COVID. (The trial received funding and design input from Pfizer.)

“We’re not sure it works,” said Krumholz, founder and director of the Yale New Haven Hospital Center for Outcomes Research and Evaluation. “What I think we need are a lot more studies of 100 people or 200 people, trying a lot more things” to treat long COVID.

Participants in the Yale trial were all highly symptomatic and lived throughout the contiguous US. Instead of having them go to participating centers, the trial came to them. “Setting up centers is expensive,” Krumholz explained, noting that the trial’s decentralized design could help cut costs and could work for a variety of conditions and treatments.

Participants were shipped the medication. They gave blood and saliva samples at a local laboratory or at home and answered questions about their symptoms in a digital diary. Yale colleague Akiko Iwasaki, PhD, who studies antiviral immunity and viral disease pathogenesis, is looking at the blood and saliva samples for differences between people who appeared to respond to nirmatrelvir-ritonavir and those who didn’t.

Paxlovid 2.0?

Meanwhile, Pfizer is working to eliminate what one recent publication referred to as nirmatrelvir-ritonavir’s Achilles’ heel: the limited metabolic stability of nirmatrelvir, a protease inhibitor that requires ritonavir to boost it to the target therapeutic range.

The problem is that ritonavir boosts the plasma levels of a long list of other medications beyond the therapeutic range, so nirmatrelvir-ritonavir is contraindicated for people taking them, unless they can temporarily stop or reduce the dose of the concomitant drugs while taking the COVID-19 treatment. Ritonavir is also the source of the metallic taste many individuals who take Paxlovid experience.

Pfizer’s second-generation protease inhibitor for treating COVID-19 is called ibuzatrelvir. Although it’s structurally related to nirmatrelvir, ibuzatrelvir has greater bioavailability when taken orally, so it doesn’t require a ritonavir boost.

Pfizer has completed a phase 2B trial testing the safety and efficacy of a 5-day course of ibuzatrelvir treatment. Participants were nonhospitalized individuals aged 18 to 65 years with confirmed COVID-19 whose symptoms began within 5 days of randomization. Ibuzatrelvir showed robust antiviral activity in the trial, with statistically significant, dose-dependent decreases in viral load at days 3 and 5 compared with placebo, Pfizer researchers reported in April at the European Congress of Clinical Microbiology and Infectious Diseases.

“It is premature to speculate on potential timing of phase 3, but we are considering next steps and plan to share updates as they are available,” Pfizer spokesperson Longley said.

Meanwhile, SARS-CoV-2 continues to evolve along with attitudes toward COVID-19, Krumholz said. Many people “are treating it like a head cold,” he explained. “They’ve obviously made the determination that it’s not dangerous, but it is dangerous.”

Published Online: September 6, 2024. doi:10.1001/jama.2024.16432

[mariacallous]

On Tuesday, the Supreme Court of the United States will hear oral arguments in a challenge to abortion pill access across the country, including in states where abortion is legal. The stakes for abortion rights are sky-high, and the case is the most consequential battle over reproductive health care access since Roe v. Wade was overturned in 2022.

At the center of this fight is mifepristone, a pill that blocks a hormone needed for pregnancy. The drug has been approved by the US Food and Drug Administration for more than two decades, and it’s used to treat some patients with Cushing’s syndrome, as well as endometriosis and uterine fibroids. But its primary use is the one contested now—mifepristone is the first of two pills taken in the first 10 weeks of pregnancy for a standard medication abortion, along with the drug misoprostol.

If the justices side with the antiabortion activists seeking to limit access to mifepristone, it could upend nationwide access to the most common form of abortion care. A ruling that invalidates mifepristone’s approval would open the door for any judge to reverse the FDA approval of any drug, especially ones sometimes seen as controversial, such as HIV drugs and hormonal birth control. It could also have a chilling effect on the development of new drugs, making companies wary of investing research into medicines that could later be pulled from the market.

Pills are now the leading abortion method in the US, and their popularity has spiked in recent years. More than six in 10 abortions in 2023 were carried out via medication, according to new data from the Guttmacher Institute. Since rules around telehealth were relaxed during the Covid-19 pandemic, many patients seeking medication abortions have relied on virtual clinics, which send abortion pills by mail. And it keeps getting more popular: Hey Jane, a prominent telemedicine provider, saw demand increase 73 percent from 2022 to 2023. It recorded another 28 percent spike comparing data from January 2023 to January 2024.

“Telemedicine abortion is too effective to not be in the targets of antiabortion folks,” says Julie F. Kay, a longtime reproductive rights lawyer and director of the advocacy group Abortion Coalition for Telemedicine.

Tomorrow’s argument comes after a long, tangled series of legal disputes in lower courts. The Supreme Court will be hearing two cases consolidated together, including FDA v. Alliance for Hippocratic Medicine, in which a coalition of antiabortion activists filed a suit challenging the FDA’s approval of mifepristone, asking for it to be removed from the market. The Alliance for Hippocratic Medicine is represented by the Alliance Defending Freedom, a right-wing Christian law firm that often takes politically charged cases.

Despite decades of scientific consensus on the drug’s safety record, the Alliance for Hippocratic Medicine has alleged that mifepristone is dangerous to women and leads to emergency room visits. A 2021 study cited by the plaintiffs to back up their claims was retracted in February after an independent review found that its authors came to inaccurate conclusions.

In April 2023, the Trump-appointed judge Matthew Kacsmaryk of the Northern District of Texas issued a preliminary ruling on the FDA case invalidating the agency’s approval of mifepristone. The ruling sent shock waves far beyond the reproductive-rights world, as it had major implications for the entire pharmaceutical industry, as well as the FDA itself; the ruling suggested that the courts could revoke a drug’s approval even after decades on the market.

The US 5th Circuit Court of Appeals narrowed Kacsmaryk’s decision a week later, allowing the drug to remain on the market, but undid FDA decisions in recent years that made mifepristone easier to prescribe and obtain. That decision limited the time frame in which it can be taken to the first seven weeks of pregnancy and put telemedicine access, as well as access to the generic version of the drug in jeopardy.

Following the 5th Circuit ruling, the FDA and Danco Laboratories sought emergency relief from the Supreme Court, asking the justices to preserve access until it could hear the case. In its legal filing, Danco aptly described the situation as “regulatory chaos.”

SCOTUS issued a temporary stay, maintaining the status quo; the court ultimately decided to take up the case in December 2023.

As all this was unfolding, pro-abortion-rights states across the country were passing what are known as shield laws, which protect medical practitioners who offer abortion care to pregnant patients in states where abortion is banned. This has allowed some providers, including the longtime medication-abortion-advocacy group Aid Access, to mail abortion pills to people who requested them in states like Louisiana and Arkansas.

Though the oral arguments before the Supreme Court begin on Tuesday, it will likely be months before a ruling. Court watchers suspect a decision may be handed down in June. With the US presidential election in the fall, the ruling may become a major campaign issue, especially as abortion access helped galvanize voters in the 2022 midterms.

If the Supreme Court agrees with the plaintiffs that mifepristone should be taken off the market, some in the pharmaceutical industry worry that it will undermine the authority of the FDA, the agency tasked with reviewing and approving drugs based on their safety and efficacy.

“This case isn't about mifepristone,” says Elizabeth Jeffords, CEO of Iolyx Therapeutics, a company developing drugs for immune and eye diseases. Jeffords is a signatory on an amicus brief filed in April 2023 that brought together 350 pharmaceutical companies, executives, and investors to challenge the Texas district court’s ruling.

“This case could have easily been about minoxidil for hair loss. It could have been about Mylotarg for cancer. It could have been about measles vaccines,” Jeffords says. “This is about whether or not the FDA is allowed to be the scientific arbiter of what is good and safe for patients.”

Greer Donley, an associate professor of law at the University of Pittsburgh and an expert on abortion on the law, doesn’t think it’s likely that the court will revoke mifepristone’s approval entirely. Instead, she sees two possible outcomes. The Supreme Court could dismiss the case or could undo the FDA’s decision in 2023 to permanently remove the in-person dispensing requirement and allow abortion by telehealth. “This would be an even more narrow decision than what the 5th Circuit did, but it would still be pretty devastating to abortion access,” she says.

The Supreme Court could also decide that the plaintiffs lack a right to bring the case to court, says David Cohen, a professor of law at Drexel University whose expertise is in constitutional law and gender issues. “This case could get kicked out on standing, meaning that the plaintiffs aren't the right people to bring this case,” he says. “If most of the questions are about standing, that will give you a sense that that's what the justices are concerned about.”

As the current Supreme Court is considered virulently antiabortion, reproductive-health-care workers are already preparing for the worst. Some telehealth providers have already floated a backup plan: offering misoprostol-only medication abortions. This is less than ideal, as the combination of pills is the current standard of care and offers the best results; misoprostol on its own can cause additional cramping and nausea. For some providers who may have to choose between misoprostol-only or nothing, it’s better than nothing.

Abortion-rights activists have no plans to give up on telehealth abortions, regardless of the outcome of this particular case. “Let us be clear, Hey Jane will not stop delivering telemedicine abortion care, regardless of the outcome of this case,” says Hey Jane’s CEO and cofounder, Kiki Freedman.

“They’re not going to stuff the genie back in the bottle,” Kay says.

[spooniestrong]

Make your voice heard and ask the CDC to:

Recommend updated 2024-2025 COVID vaccines for all ages AND

Strengthen our vaccine drive by recommending more frequent boosting (at least every six months) and more frequent updates to the vaccines, adjusted for the latest variants.

Submit a public comment using our sample language below.

You can also register to give Oral Public Comment at the upcoming June 26-28 online CDC ACIP Meeting at: https://www2.cdc.gov/vaccines/acip/acip_publiccomment.asp 

Submit written comments and/or register to make oral comments at the meeting by Monday, June 17 at 11:59pm Eastern Standard Time.

It’s important to submit a personalized comment, which can be brief. Ideas for a personalized comment:

How you, your family, or your community would be impacted by fall vaccine eligibility being restricted to only high risk groups (such as older age or immunocompromised status)

Barriers to vaccination your have faced, particularly if your eligibility was questioned or misinterpreted by a vaccine provider

How out-of-pocket costs are a barrier to getting the latest vaccines

Also feel free to take inspiration from or borrow the language in our sample public comment below.

Docket No. CDC–2024–0043

Updated 2024-2025 COVID vaccines must be recommended for people of all ages, regardless of health status. A restrictive approach to eligibility would create undue barriers for vulnerable people and discourage high risk people from getting needed vaccine boosters.

The vaccine schedule should address waning efficacy in the months following vaccination [1-3] as well as emergence of new SARS-CoV-2 strains by recommending updated vaccination for all ages, at least every six months. Recent vaccination is also associated with a lower risk of developing Long COVID following a COVID infection [4] as well as a lower risk of Multisystem Inflammatory Syndrome in children (MIS-C) [5]. 

The CDC’s clear and unequivocal recommendation of updated COVID vaccination for all ages will influence what healthcare providers recommend, and what health insurances cover. Moreover, it will improve public awareness regarding the need for updated vaccination.

The CDC must ensure equitable and affordable access to updated vaccines and prevent limited access because of financial constraints or demographics. The CDC’s Bridge vaccine access program is slated to end August 2024 and must be extended to ensure uninsured and underinsured people have access to the updated vaccines this fall [6].

References:

1. Link-Gelles R. Effectiveness of COVID-19 (2023-2024 Formula) vaccines. Presented at: FDA VRBPAC Meeting; June 5, 2024. Accessed June 12, 2024. https://www.fda.gov/media/179140/download

2. Wu N, Joyal-Desmarais K, Vieira AM, et al. COVID-19 boosters versus primary series: update to a living review. The Lancet Respiratory Medicine. 2023;11(10):e87-e88. doi:10.1016/S2213-2600(23)00265-5

3. Menegale F, Manica M, Zardini A, et al. Evaluation of Waning of SARS-CoV-2 Vaccine–Induced Immunity: A Systematic Review and Meta-analysis. JAMA Netw Open. 2023;6(5):e2310650. doi:10.1001/jamanetworkopen.2023.10650

4. Fang Z, Ahrnsbrak R, Rekito A. Evidence Mounts That About 7% of US Adults Have Had Long COVID. JAMA. Published online June 7, 2024. doi:10.1001/jama.2024.11370

5.  Yousaf AR. Notes from the Field: Surveillance for Multisystem Inflammatory Syndrome in Children — United States, 2023. MMWR Morb Mortal Wkly Rep. 2024;73. doi:10.15585/mmwr.mm7310a2

6. https://www.cdc.gov/vaccines/programs/bridge/index.html 

Full instructions for written and oral comment and meeting information can be found at: https://www.cdc.gov/vaccines/acip/meetings/index.html

You can also register to give Oral Public Comment at the upcoming June 26-28 online CDC ACIP Meeting at: https://www2.cdc.gov/vaccines/acip/acip_publiccomment.asp 

You must register by June 17 at 11:59pm Eastern Standard Time

CDC’s ACIP meeting information on the Federal Register: https://www.federalregister.gov/documents/2024/05/24/2024-11439/meeting-of-the-advisory-committee-on-immunization-practices 

Vaccination with the latest updated vaccines continues to be foundational to a multilayered approach to COVID, providing protection against both acute disease and Long COVID. Far too few Americans have received the latest vaccines. Only approximately 22.6% of adults and 14.8% of children have received the latest 2023-2024 vaccines (as of June 1, 2024), which have been available since Fall 2023. COVID vaccination rates in both groups lags far behind influenza vaccination rates. Only 7.1% of adults aged 65 and older received the recommended two doses of the 2023-2024 vaccine (as of April 27, 2024).

Vaccine efficacy wanes significantly four to six months following vaccination, making updated vaccination important for all people as COVID continues to spread in our communities. Vaccine approaches that restrict access based on age or risk status put all of us at risk and leave those at high risk of severe consequences of COVID infection confused about whether they qualify to receive additional doses. A more frequent vaccination approach providing vaccination at least every six months as well as frequent updates to match current variants is needed to better protect all of us amid year-round COVID spread.

The CDC’s Bridge Access Program, which provides COVID vaccines to uninsured and underinsured adults free of charge, is due to end August 2024. The end of this program will unnecessarily put vulnerable people at risk, and public health officials must advocate for continuation and expansion of this program.

Submitted written comments or registration to make oral comments at the meeting must be received by the CDC no later than June 17 at 11:59pm Eastern Standard Time

[newlevant]

¡Aquí tenemos! Sobre el COVID y cómo puedes protegerte: edición de 2024

Traducción al castellano por Maru Florián Padrón (twitter: @unlocalizedling). ¡Todes pueden imprimir estas zines gratis!

Reportes nacionales semanales sobre la concentración efectiva de SARS-CoV-2 virus en las aguas residuales: https://pmc19.com/data/

biobot.io/data/covid-19

La Red Española de Investigación en COVID persistente: reicop.org

Las vacunas contra el covid actualizadas intentan coincidir con las variantes del covid que circulan actualmente, por lo que vale la pena adquirirlas. Simplemente no te hacen invencible.

Encuentre vacunas en los EEUU: https://vacunas.gov

Pide pruebas de covid gratuitas (si están incluidas en la cobertura de tu seguro médico): fastlabtech.com

Encuentra puntos gratuitos dónde realizarte una prueba: https://testinglocator.cdc.gov/homees

Cómo obtener una muestra: https://ontariohealth.ca/sites/ontariohealth/files/2022-05/RAT-Oral-nasal-collection-instructions-Spanish.pdf

Pruebas de ajuste facial y ajuste respiratorio por 3M: 3m.com.es

Compre un respirador 3M Aura: stauffersafety.com

Resultados de la prueba de talla: testtheplanet.org

Cómo hacer un filtro HEPA casero: https://renovablesverdes.com/filtro-hepa-casero/

Precaución: ¡el xilitol es venenoso para perros y gatos! Mantenga el aerosol nasal alejado de ellos.

Estudios sobre los sprays nasales (en inglés) aquí: https://newlevant.com/covidzine/es

Qué hacer si tiene COVID por el People's CDC: peoplescdc.org/es/2023/01/10/what-to-do-if-you-have-covid/…

Qué hacer cuando tengo COVID por Clean Air Club, con información relevante��si vives en España: https://dropbox.com/scl/fi/999mutp

Encontrar un sitio de Pruebas para Tratar o un sitio del Programa de Asistencia a Pacientes de Paxlovid: https://treatments-es.hhs.gov

Virtual ExpressCare en NY: https://ondemand.expresscare.video/landing

Suplementos recomendados por RTHM Health (inglés): https://rthm.com/articles/youve-got-covid/

Gracias por leer. ¡Puedes imprimir y distribuir tus propias copias de este zine!

Referencias y más recursos aquí: http://newlevant.com/COVIDzine/es

Cualquier error en español es mío porque utilicé el traductor de Google. Maru tradujo muy bien el zine.

[gumjrop]

The FDA, between now and May 8, is accepting public comments for their upcoming vaccine committee meeting. Let them know that all of us need access to COVID vaccines at least twice a year.

Make your voice heard and ask the FDA Vaccines and Related Biological Products Advisory Committee Meeting to:

Ensure vaccine manufacturers anticipate the upcoming dominant strain of SARS-CoV-2.

Recommend updated COVID vaccines for all ages AND

Strengthen our vaccine drive by recommending more frequent boosting (at least every six months) and more frequent updates to the vaccines, adjusted for the latest variants.

Submit a public comment. Feel free to use our sample language below.

You can also register to give Oral Public Comment at the upcoming May 16 online FDA Vaccines and Related Biological Products Advisory Committee Meeting at: CBERVRBPAC@fda.hhs.gov on May 1, 2024. THAT’S TONIGHT!

Submitted written comments for the meeting must be received by the FDA via the Federal Register no later than May 8, 2024 at 11:59 Eastern Daylight Time. 

It’s important to submit a personalized comment, which could include the importance of anticipating the next dominant viral strain, the lack of vaccine access that has impacted or would impact you, or how out-of-pocket costs are a barrier in your family or community. Feel free to take inspiration from or borrow the language in our sample public comment below.

Docket No. FDA–2024–N–0970 Scientific evidence indicates updated vaccines are needed to address the ongoing changes in COVID variants, and they should ideally be allowed, available, and fully covered by public funds and/or insurance, for people of all ages at least every six months. The vaccine schedule should address waning efficacy in the months following vaccination [1-3] as well as emergence of new SARS-CoV-2 strains. The FDA’s decision will affect the current and future vaccine approach including what healthcare providers recommend, what health insurance covers, and level of public engagement. It is of utmost importance that the FDA anticipates the newest viral variants and provides recommendations that anticipates the next dominant strain in the next six months. This requires that the FDA ensure that manufacturers anticipate the newest variants. Restricting vaccinations to only annual updates misses an opportunity, given that there is the potential to update the vaccines to better match perpetually emerging variants. Updates to all vaccine types are needed, and mRNA vaccines are particularly suited to frequent updates. The recommendation for only annual vaccination also creates barriers for vulnerable people and discourages high risk people from getting needed vaccine boosters. The FDA must ensure support equitable and affordable access to updated vaccines and prevent limited access because of financial constraints or demographics by advocating for programs such as the CDC’s bridge program that ensures no cost access. [4] References:

Link-Gelles R. COVID-19 vaccine effectiveness updates. Presented at: FDA VRBPAC Meeting; June 15, 2023. Accessed February 9, 2024. https://www.fda.gov/media/169536/download

Wu N, Joyal-Desmarais K, Vieira AM, et al. COVID-19 boosters versus primary series: update to a living review. The Lancet Respiratory Medicine. 2023;11(10):e87-e88. doi:10.1016/S2213-2600(23)00265-5

Menegale F, Manica M, Zardini A, et al. Evaluation of Waning of SARS-CoV-2 Vaccine–Induced Immunity: A Systematic Review and Meta-analysis. JAMA Netw Open. 2023;6(5):e2310650. doi:10.1001/jamanetworkopen.2023.10650

https://www.cdc.gov/vaccines/programs/bridge/index.html 

Full instructions for written and oral comment and meeting information can be found at: https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-may-16-2024-meeting-announcement

FDA Vaccines and Related Biological Products Advisory Committee Meeting on the Federal Register: https://www.federalregister.gov/documents/2024/03/04/2024-04523/vaccines-and-related-biological-products-advisory-committee-notice-of-meeting-establishment-of-a

[genderqueerblog]

For what it's worth I really do feel like high risk groups do deserve to be more well protected than someone with only typical risk

Context: I reblogged a post saying that the CDC is going to "limit" access to the newest COVID vaccine to only the elderly, pregnant, and immunocompromised, and calling on people to submit public comments.

The post in question actually seems to be OP jumping to conclusions completely. I think I'll delete it after I post this. The CDC is not "restricting" the latest vaccine to "high-risk" groups; what they're doing is not recommending it to people who aren't "high-risk," which is also very bad, but is not the same thing. If you go to the doctor and ask for a COVID vaccine, they are not going to say "No, you can't have it because you're not high-risk."

In general, yes, the higher a person's risk, the more protection they should have... but first you have to agree on what "typical risk" and "high risk" mean, and what the appropriate, corresponding protection levels are. People at "typical risk" from COVID-19 are still at pretty high risk! Besides which, a huge part of how protections against disease work is by mass participation. A healthy person who lives in an area with a 20% vaccination rate is at much higher risk of infection than an equally healthy person living in an 80% vaccinated area. The problem with the CDC only recommending vaccines to limited groups is not that they're providing more protection to people who need more protection, it's that they're not providing enough protection for anyone. Even vaccinated "high-risk" people are less safe if the "low-risk" people around them aren't vaccinated, and even "low-risk" people are way higher risk than the CDC is willing to acknowledge!

Anyway, tell the CDC that all ages need updated vaccine access.

PCDC's sample public comment:

Docket No. CDC–2023–0060 Scientific evidence indicates the updated vaccines should ideally be allowed, available, and fully covered by public funds or insurance, for people of all ages at least every six months.  The vaccine schedule should address waning efficacy in the months following vaccination [1] as well as new variants. The CDC’s decision will affect everything about the current and future vaccine approach including what healthcare providers recommend, what health insurance covers, and what the public decides is needed.  Restricting vaccinations to only annual updates misses an opportunity to update vaccines on a more frequent basis as divergent variants are identified, given that there is the potential to quickly update mRNA vaccines to better match perpetually emerging variants. The recommendation for only annual vaccination also creates barriers for vulnerable people and discourages high risk people from getting needed boosters. The CDC must ensure equitable access to updated vaccines and prevent limited access because of financial constraints or demographics by expanding and indefinitely extending the COVID Vaccine Bridge Access Program [2]. References: 1. https://www.fda.gov/media/169536/download  2. https://www.cdc.gov/vaccines/programs/bridge/index.html

CDC’s ACIP Meeting Information (Including how to register to make an Oral Public Comment): https://www.cdc.gov/vaccines/acip/meetings/index.html

Submit a written comment: https://www.regulations.gov/document/CDC-2023-0060-0001

[darkmaga-retard]

https://www.globalresearch.ca/un-forced-admit-gates-funded-vaccine-causing-polio-outbreak-africa/5723137

UN Forced to Admit Gates-funded Vaccine Is Causing Polio Outbreak in Africa

By 21st Century Wire

Global Research, September 05, 2024

21st Century Wire 4 September 2020

The United Nations has been forced to admit that a major international vaccine initiative is actually causing a deadly outbreak of the very disease it was supposed to wipe-out.

While international organisations like the World Health Organization (WHO) will regularly boast about ‘eradicating polio’ with vaccines—the opposite seems to be the case, with vaccines causing the deaths of scores of young people living in Africa.

Health officials have now admitted that their plan to stop ‘wild’ polio is backfiring, as scores children are being paralyzed by a deadly strain of the pathogen derived from a live vaccine – causing a virulent wave of polio to spread.

This latest pharma-induced pandemic started out in the African countries of Chad and Sudan, with the culprit identified as vaccine-derived polio virus type 2.

Officials now fear this new dangerous strain could soon ‘jump continents,’ causing further deadly outbreaks around the world.

Shocking as it sounds, this Big Pharma debacle is not new. After spending some $16 billion over 30 years to eradicate polio, international health bodies have ‘accidentally’ reintroduced the disease to in Pakistan, Afghanistan, and also Iran, as the central Asia region was hit by a virulent strain of polio spawned by the a pharmaceutical vaccine. Also, in 2019, the government of Ethiopia ordered the destruction of 57,000 vials of type 2 oral polio vaccine (mOPV2) following a similar outbreak of vaccine-induced polio.

The same incident has happened in India as well.

It’s important to note that the oral polio vaccine is being pushed by the Global Polio Eradication Initiative (GPEI), a consortium which is supported and funded by the Bill & Melinda Gates Foundation.

All of this should be cause for concern, especially with western governments and transnational pharmaceutical giants all rushing to roll-out their new Gates-funded experimental coronavirus vaccine for the global population.

Currently, the first experimental COVID-19 vaccine is being tested on the African populationthrough GAVI Vaccine Alliance, another organization funded by the Gates Foundation. A large round of human trials is taking place in South Africa, run by the University of the Witwatersrand in Johannesburg—another Gates-funded institution.

[beardedmrbean]

Parents in Oregon are calling to replace a local school board following reports of a sexually explicit book in the curriculum and at least two instances where a teacher organized activities discussing sexual acts.

Fox News Digital previously reported how health class students who missed coursework at Churchill High School in Eugene, Oregon, were asked via Canvas, an online learning management system, to complete a 10-point assignment titled "Fantasy Story."

"For those students who were absent, you will write a short story of a paragraph or two. This story is a sexual fantasy that will have NO penetration of any kind or oral sex (no way of passing an STI)."

The assignment from teacher Kirk Miller also asked students to choose three items, such as candles, massage oil, feathers and flavored syrup, to use in the story.

But parent Justin McCall said his older daughter, who is in the 10th grade at Churchill High School, revealed the assignment had also been conducted in class and that the teacher had asked students to pick the sexual items written on a piece of paper out of a hat that he passed around.

Further scrutiny of the "Health 2 Human Sexuality" class found that students were also allegedly given an assignment called "With Whom Would You Do it." The project involved a virtual spinning wheel labeled with sexual categories. Students were allegedly instructed to respond when the wheel stopped and write the initials of the person they would engage in the sex act with.

"My daughter told me it was literally up on the board and it mentioned you know who are you going to have anal penetration with, oral sex, licking of the ear, kissing and vaginal sex," McCall said, calling the assignment "disgusting and wrong."

A Title VI and IX coordinator attempted to speak with McCall's daughter about the incidents but was directed to the family's legal counsel.

The Eugene 4J School District did not return Fox News Digital’s request for comment.

The above allegations, as well as a flurry of other complaints from parents, have prompted calls for new leadership on the Eugene School Board, which is holding elections in May. In the event leadership stays the same, a group of parents is in the process of knocking on doors and setting up tables outside the district schools to gather signatures for a recall.

Beth Ball, a 4J alumni who met her husband at Churchill High School in the 1990s, intentionally enrolled her children in the 4J school district following her positive educational experience. Her issues began when her child entered sixth grade at the Arts & Technology Academy in Eugene.

At home, Ball noticed a form that said she could opt her child out of health class if she disagreed with the contents of the syllabus or curriculum. However, after correspondence with the teacher, Ball was told the syllabus and curriculum had not yet been created and waited at the school for two days to get a meeting with the principal.

The principal informed her they could not access the syllabus and curriculum, but her child needed to be enrolled in health class to graduate. Given the lack of information, Ball instructed her child to wait in the office daily during health class. Her child received a "no pass" in the class, but because of COVID-19 school closures, the "no-pass" became a non-issue.

Once her child entered the ninth grade at Churchill, the same school Ball attended, he was assigned a novel called "I'll Give You the Sun."

"The first five pages of it the book talks about how [the main character] is getting beat up and he's turned on by it. He gets a boner," Ball said. "For me, that's completely unacceptable because it's saying that if you're getting abused or picked on, it's normal and in fact you should like it."

A review of the book by Fox News Digital found the scene described by Ball and takes place early in the book when the main character wrestles with another student. 

After contacting the school to ask why the book was placed in the curriculum, she was simply told that it got great reviews and spurred conversation on complex topics. She then pulled her child out of Churchill and began homeschooling him.

"And then this sexual essay hit, and I wasn't surprised in the least," Ball said.

Following the backlash, school principal Missy Cole said, "the district has begun the process of reviewing and selecting a new health curriculum to replace the OWL content that will be completed by the end of the school year."

According to the board, the changes to the curriculum were not related to complaints from parents and had already been on the docket for the 2023 school year.

During a March 16 school board meeting, citing "failures in our practices," Eugene School District Superintendent Andy Dey said they had identified "shortcomings" in their curriculum and recommended that the sexual fantasy's lesson not be administered again.

Dey also said the rumors of "spinning wheels" with "salacious acts" had not been substantiated or reflected in the materials the teachers used. However, Dey did confirm an "online virtual randomizer wheel" that did not have sexual acts on it.

He also said that the sexual fantasy's assignment was given out due to "inadequate oversight" and that future lessons will follow the curriculum verbatim and refrain from using supplemental materials, as was done in this case.

In a statement to the New York Post, OWL program manager Melanie Davis said the district was following an "unauthorized" and "out-of-context" facilitated group activity currently out of print.

The United Church of Christ and the Unitarian Universalist Association claimed the material was not part of the comprehensive OWL curriculum it helped to develop.

Emails provided to Fox News Digital showed that McCornack Elementary asked McCall to sign paperwork agreeing to only correspond with the school over email and only through his wife and noted McCall was trespassed off the property "due to hostile behavior towards other McCornack parents, students, and staff that created fear."

McCall was allowed to speak at the March 16 board meeting despite his ban from the elementary school. Following his public comments at the meeting and his move to recall the board, McCall was banned from all 4J district property. The district said they contact McCall no later than April 20 about his formal complaints and trespass appeal.

At the meeting, McCall claimed the school was lying about the spinning wheel assignment and suggested the teacher had not yet been fired because he is also the football coach and the team was doing well.

"If you do not remove him, I'm giving you my word today that tomorrow morning I will go down to the County Clerk's office and I will file for the removal of every single one of you," he said as the room erupted in cheers.

Miller has been placed on administrative leave.

Dr. Michael Bratland, a local dentist and conservative running for school board in the May elections, said that he wants a comprehensive review of the situation but stopped short of supporting the termination of the teacher or board members. He also credited Superintendent Dey for his leadership and handling of the situation but was more critical of the current board.

"The school board's the top and they need to take responsibility and when I was at that school board meeting last week, I didn't really hear anybody take accountability," he said.

[harrispharmacy]

Independent Community Pharmacy serving Luton and it's surrounding areas. We go out of our way to ensure every customer leaves our pharmacy with a smile on their face. Our pharmacy stocks many items including cosmetics, aftershaves, perfumes, toiletries, baby accessories and food and many pharmacy medications. We offer travel vaccinations for all patients. If you are travelling to anywhere give us a call or pop in store and we will offer all travel advice to make your trip that much better! We also have a free delivery service for all of our patients.

Services: COVID-19 TESTING

CPCS VIA NHS 111

DISCHARGE MEDICATION SERVICE

EMERGENCY CONTRACEPTION

HEALTHIER LIVING: Alcohol Reduction, Smoking Cessation, Weight Loss

MEN'S HEALTH: Erectile Dysfunction, Hair Loss, Premature Ejaculation, Urinary Incontinence

NEW MEDICATION SERVICE

SEASONAL FLU SERVICE

SEASONAL HEALTH SERVICES: Flu Jab / Vaccinations, Flu test n' treat, Hayfever, Pneumococcal Vaccine, Respiratory Issues, Salbutamol Inhaler, Strep A.

SEXUAL HEALTH: Chlamydia, Erectile Dysfunction, Gonorrhea, HIV Testing, Morning After Pill, Oral Contraception, Premature Ejaculation, Thrush, Urinary Tract Infection

SKIN CARE: Acne, Cold Sore, Dermatitis, Facial Hair Removal, Fungal Infection, Hives, Impetigo, Psoriasis (plaque), Psoriasis (scalp), Rosacea

SMOKING CESSATION SERVICE

SUBSTANCE DEPENDENCE

VACCINATIONS: Chicken Pox, Flu, Hepatitis B, HPV, Meningitis ACWY, Meningitis B, MMR, Pneumonia, Shingles, Tuberculosis

WOMEN'S HEALTH: Chlamydia, Facial Hair Removal, Morning After Pill, Oral Contraception, Period Delay, Thrush, Urinary Tract Infection, Weight Loss

Website: https://www.harrischemist.co.uk

Address: 165 a/b Dunstable Road, Luton, Bedfordshire, LU1 1BW

Phone Number: 01582 400851

Business Contact Email ID: harrispharmacy165@gmail.com

Business Hours: Monday - Friday : 09:00 AM - 07:00 PM Saturday : 09:30 AM - 01:00 PM

[aramdental]

Discover the Leading Dental Clinic in Thiruvanmiyur: Expert Care and Advanced Services

Advantages of Choosing the Best Dental Clinic in Thiruvanmiyur, Chennai

When it comes to oral health, choosing the right dental clinic is crucial. Thiruvanmiyur, a prominent area in Chennai, is home to several well-established dental clinics. However, selecting the best one can significantly affect the quality of care you receive. The best dental clinic in Thiruvanmiyur stands out for its comprehensive services, advanced technology, experienced professionals, and patient-centric approach. Here are some key advantages of opting for the top dental clinic in this region.

Comprehensive Range of Services

One of the main advantages of choosing the best dental clinic in Thiruvanmiyur is access to a wide range of dental services under one roof. These clinics offer routine check-ups and cleanings to advanced procedures like dental implants, root canal treatments, cosmetic dentistry, and orthodontics. Whether you need preventive care, restorative treatments, or aesthetic One of the main advantages of choosing the best dental clinic in Thiruvanmiyur is access to a wide range of dental services under one roof. enhancements, the best clinics cater to all your dental needs, ensuring a seamless experience without visiting multiple specialists.

Highly Skilled and Experienced Dentists

The best dental clinics in Thiruvanmiyur boast a team of highly qualified and experienced dentists who are specialists in their respective fields. Whether it’s general dentistry, oral surgery, or cosmetic procedures, these clinics ensure that their staff undergo continuous training and education to stay updated with the latest advancements in dental care. Their expertise helps in accurate diagnosis, effective treatment planning, and successful outcomes, giving you confidence that you are in safe hands.

Cutting-Edge Technology

Modern dental care has evolved significantly with advanced technology, and the best dental clinics in Thiruvanmiyur are at the forefront of these innovations. These clinics have state-of-the-art tools such as digital X-rays, intraoral cameras, laser dentistry equipment, and CAD/CAM technology for precise and efficient treatments. Such advanced technology ensures faster procedures, more accurate diagnoses, and minimally invasive therapies, making the entire process comfortable and safe for patients.

Personalized and Patient-Centric Care

What truly sets the best dental clinic apart is its commitment to providing personalized care. Each patient is unique, and so are their dental needs. The top clinics focus on understanding your concerns and developing customized treatment plans accordingly. They also prioritize patient comfort, taking extra care to create a welcoming and calming environment, especially for those who may experience anxiety about dental procedures. Everything is tailored to ensure a positive patient experience, from friendly staff to detailed consultations.

Strict Hygiene and Safety Protocols

In the wake of the COVID-19 pandemic, hygiene and safety have become even more crucial in medical settings. The best dental clinics in Thiruvanmiyur adhere to stringent hygiene protocols, ensuring the highest standards of cleanliness and sterilization. These clinics follow all the guidelines to maintain a safe environment for patients and staff. These safety measures add an extra layer of assurance, from disinfecting treatment rooms between appointments to using single-use instruments where applicable.

Convenient Location and Accessibility

Thiruvanmiyur is a well-connected area in Chennai, and the best dental clinics here are easily accessible. Conveniently located near public transport options and with ample parking facilities, these clinics make it hassle-free for patients to schedule and attend their appointments. Accessibility is a crucial factor, especially in dental emergencies where prompt care is required.

Transparent Pricing and Insurance Support

The best dental clinics in Thiruvanmiyur prioritize transparency in pricing, ensuring that patients are well-informed about the costs involved in their treatment plans. Many of these clinics also offer support with insurance claims, making it easier for patients to manage their finances while receiving top-notch dental care. Clear communication about fees and payment options ensures no hidden costs, helping build trust and long-term relationships with patients.

Conclusion

Choosing the best dental clinic in Thiruvanmiyur, Chennai, provides many advantages, from expert care and advanced technology to personalized service and transparent pricing. By opting for a clinic that prioritizes your oral health and overall well-being, you can ensure that your dental visits are comfortable, efficient, and effective. Combining a skilled team, comprehensive services, and a patient-centric approach makes these clinics a top choice for anyone seeking high-quality dental care in Thiruvanmiyur.

[deshpandeisha]

Advances in Patient Temperature Monitoring: Innovations and Technologies

The global patient temperature monitoring market size is expected to reach USD 5.85 Billion in 2030 and register a steady revenue CAGR of 6.4% during the forecast period, according to latest analysis by Emergen Research. Growing population as well as increasing occurrence of infectious diseases is a major factor driving market revenue growth. The world's population is expected to grow by over 2 billion individuals during the next 30 years, from 8 billion presently to 9.7 billion in 2050, with a peak of around 10.4 billion in the mid-2080s. Foodborne diseases, notably Campylobacteriosis, have a huge impact, hence approximately one in ten individuals fall ill each year and 33 million healthy life years are lost. During the course of many infectious diseases, body generates fever. As a result of growing worldwide population and prevalence infectious illnesses, there is a greater need for accurate patient temperature monitoring.

Request a Sample Report with Table of Contents and Figures to click Here: https://www.emergenresearch.com/request-sample/1576

Competitive Terrain:

The section on the competitive landscape offers valuable and actionable insights related to the business sphere of the Patient Temperature Monitoring market, covering extensive profiling of the key market players. The report offers information about market share, product portfolio, pricing analysis, and strategic alliances such as mergers and acquisitions, joint ventures, collaborations, partnerships, product launches and brand promotions, among others. The report also discusses the initiatives taken by the key companies to combat the impact of the COVID-19 pandemic.

The leading market contenders listed in the report are:

Cardinal Health, Koninklijke Philips N.V., 3M, Drägerwerk AG & Co. KGaA, BD, OMRON Healthcare, Inc., Masimo, BRAUN GMBH Industrie-Elektronik, Terumo Corporation, and PAUL HARTMANN AG

Click to access the Report Study, Read key highlights of the Report and Look at Projected Trends: https://www.emergenresearch.com/industry-report/patient-temperature-monitoring-market

Emergen Research has segmented the global Patient Temperature Monitoring market on the basis of type, application, end-use, and region:

Segments Covered in this report are:

Product Outlook (Revenue, USD Billion; 2019–2030)

Wearable Continuous Monitoring Sensors

Smart Temperature Monitoring Patches

Table-Top Temperature Monitoring Devices

Non–Invasive Vital Signs Monitoring Devices

Continuous Core Body Temperature Monitoring Devices

Handheld Temperature Monitoring Devices

Mercury Thermometers

Digital Thermometers

Infrared Thermometers

Invasive Temperature Monitoring Devices

Site Outlook (Revenue, USD Billion; 2019–2030)

Non-Invasive Temperature Monitoring Devices

Oral Temperature Monitoring

Axillary and Temporal Artery Temperature Monitoring

Tympanic Membrane Temperature Monitoring

Invasive Temperature Monitoring Devices

Esophageal Temperature Monitoring

Nasopharynx Temperature Monitoring

Urinary Bladder Temperature Monitoring

Rectal Temperature Monitoring

Application Outlook (Revenue, USD Billion; 2019–2030)

Pyrexia

Hypothermia

Blood Transfusion

Anesthesia

Other applications

The various regions analyzed in the report include:

North America (U.S., Canada)

Europe (U.K., Italy, Germany, France, Rest of EU)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

Key Objectives of the Report:

Analysis and estimation of the Patient Temperature Monitoring Market size and share for the projected period of 2022-2030

Extensive analysis of the key players of the market by SWOT analysis and Porter’s Five Forces analysis to impart a clear understanding of the competitive landscape

Study of current and emerging trends, restraints, drivers, opportunities, challenges, growth prospects, and risks of the global Patient Temperature Monitoring Market

Analysis of the growth prospects for the stakeholders and investors through the study of the promising segments

Strategic recommendations to the established players and new entrants to capitalize on the emerging growth opportunities

Request Customization as per your specific requirement@ https://www.emergenresearch.com/request-for-customization/1576

[colinwilson11]

The Non-Viral Drug Delivery Systems Market To Grow Owing To Increasing Advantages Over Viral Delivery Methods

Non-viral drug delivery systems have gained immense popularity in recent years owing to their advantages over viral delivery methods including low immunogenicity, larger transgene capacity and ease of production. Non-viral techniques involve encapsulating drugs into nanoparticles, liposomes or conjugating them to targeting moieties and are generally considered safer than viral vectors.

The Non-Viral Drug Delivery Systems Market is estimated to be valued at US$ 8.1 Bn in 2024 and is expected to exhibit a CAGR of 13% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the non-viral drug delivery systems market are Arcturus Therapeutics, Bio-Path Holdings, CureVac, Entos Pharmaceuticals, eTheRNA Immunotherapies. The companies are investing heavily in R&D to develop novel non-viral vectors with higher efficiency and safety. The growing demand for targeted drug delivery systems is a major factor driving the non-viral drug delivery systems market. Non-invasive therapeutic delivery through oral, transdermal and inhalation routes has gained prominence. Technological advancements like lipid nanoparticles, polymeric nanoparticles and conjugation with cell-penetrating peptides have increased the delivery of macromolecules.

Market Trends

One of the major trends in the non-viral drug delivery systems market is the rising focus on gene therapy. Non-viral gene delivery methods offer less immunogenic and inflammatory responses making them safer for repeated administration. mRNA-based therapies and applications in cancer immunotherapy are emerging as lucrative opportunities. Another key trend is the development of stimuli-responsive delivery systems that are designed to release drug payloads in response to specific biochemical cues like pH, redox potential or enzymatic activity at the site of action.

Market Opportunities

Targeted delivery to tumors using actively/passively targeted nanoparticles presents a huge opportunity. The application of nanotechnology has allowed efficient delivery of anti-cancer drugs, imaging agents and nucleic acids selectively to tumor tissues. Oligonucleotide therapeutics also offer lucrative opportunities given the advances in mRNA vaccines. Non-invasive delivery through pulmonary route for treatment of lung cancers and respiratory diseases is an emerging area of focus.

Impact Of COVID-19 On Non-Viral Drug Delivery Systems Market Growth

The COVID-19 pandemic has significantly impacted the non-viral drug delivery systems market. During the initial phases of the pandemic, most non-essential research was put on hold or delayed, impacting the development of new drug delivery technologies. Companies focused their efforts on developing COVID-19 vaccines and therapeutics to address the urgent medical need. This diverted resources away from other drug delivery applications.

However, as the pandemic progressed, companies recognized the long-term market potential for non-viral delivery platforms to address future pandemics and other diseases. Nanoparticle-based delivery systems can effectively transport mRNA, DNA and protein therapeutics into cells, making them well-suited for developing new classes of antiviral drugs and vaccines. Several companies utilized their non-viral platforms to design COVID-19 vaccines and therapies during clinical trials.

Going forward, governments and healthcare agencies are expected to prioritize research into development capabilities for rapid responses to health emergencies. Non-viral delivery technologies can play a major role here through their ability to package different types of biologics and enable faster discovery processes compared to viral vectors. Companies are also advancing formulations tuned for stability at varying temperatures and extended shelf-life to address logistical challenges in vaccine distribution globally.

North America Dominates Non-Viral Drug Delivery Systems Market

The North America region currently dominates the Non-Viral Drug Delivery Systems Market in terms of value. This is due to presence of established pharmaceutical and biotechnology companies engaged in development and commercialization of delivery platforms for various biologics. Large companies have made significant investments setting up research centers focused on non-viral technologies.

Government funding for innovation is also strong through the National Institute of Health and Department of Defense programs. Academic research is rapidly advancing new formulations and delivery routes. The U.S. and Canada also have a well-developed regulatory system to approve new drug-device combination products incorporating non-viral carriers. High healthcare spends per capita contribute to faster market uptake of advanced therapeutics enabled by these platforms.

Asia Pacific Emerging As Fastest Growing Region

Going forward, the Asia Pacific region is expected to offer the fastest market growth opportunities for non-viral drug delivery systems. This is attributable to rising chronic disease prevalence in highly populated countries like China and India. Governments are investing significantly to build local R&D capabilities through initiatives such as the Made in China 2025 policy.

Countries like South Korea and Japan also have large biotechnology industries focusing on formulations. At the same time, reduced manufacturing and labor costs are attracting global pharmaceutical companies to outsource production to Asia Pacific contract development and manufacturing organizations. This will help expand regional production capacities for various non-viral technologies.

Get more insights on this topic:  https://www.ukwebwire.com/non-viral-drug-delivery-systems-market-are-estimated-to-witness-high-growth-owing-to-advancements-in-nanotechnology/

About Author:

Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement. (LinkedIn - https://www.linkedin.com/in/priya-pandey-8417a8173/)

What Are The Key Data Covered In This Non-Viral Drug Delivery Systems Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Non-Viral Drug Delivery Systems Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Non-Viral Drug Delivery Systems Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Non-Viral Drug Delivery Systems Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Non-Viral Drug Delivery Systems Market vendors

FAQ’s

Q.1 What are the main factors influencing the Non-Viral Drug Delivery Systems Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Non-Viral Drug Delivery Systems Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Non-Viral Drug Delivery Systems Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it